Literature DB >> 11352733

In vitro assembly of tau protein: mapping the regions involved in filament formation.

M Pérez1, M Arrasate, E Montejo De Garcini, V Muñoz, J Avila.   

Abstract

Unraveling the mechanism of self-assembly of the protein tau into paired helical filaments (PHFs) is a crucial step toward the understanding of Alzheimer's and other neuropathological diseases at the molecular level. In an effort to map the role of different regions of tau in the mechanism of self-assembly, we have studied the polymerization ability of different tau fragments using an in vitro assay. Our results indicate that the N-terminal domain interferes with tau's ability to polymerize in vitro. The effect seems to be size dependent. Particularly, an isoform of tau from the peripheral nervous system, which has a much larger N-terminal domain, was found unable to form filaments in our in vitro assay. This finding can explain why in Alzheimer's patients PHFs only accumulate in the neurons from the central nervous system. We also report that a short segment of tau located in the third microtubule binding repeat (residues 317 to 335, peptide 1/2R) is probably the minimal segment of that region able to grow into filaments in vitro and in the presence of heparin. In contrast with whole peptide 1/2R, peptides corresponding to either the N-terminal or C-terminal halves of this segment were unable to form filaments. Finally, our polymerization studies of peptides from the C-terminal domain reveal a short sequence spanning residues 391 to 407 that grows into filaments in vitro. This tau segment forms filaments regardless of whether is incubated with heparin. Moreover, such filaments differ in diameter and morphology, suggesting a different mechanism of self-assembly.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11352733     DOI: 10.1021/bi002961w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  19 in total

1.  Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.

Authors:  Leonel E Rojo; Jans Alzate-Morales; Iván N Saavedra; Peter Davies; Ricardo B Maccioni
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

Review 2.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

3.  Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity.

Authors:  Alejandra del C Alonso; Bin Li; Inge Grundke-Iqbal; Khalid Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

4.  Tau pathology-mediated presynaptic dysfunction.

Authors:  H Moreno; G Morfini; L Buitrago; G Ujlaki; S Choi; E Yu; J E Moreira; J Avila; S T Brady; H Pant; M Sugimori; R R Llinás
Journal:  Neuroscience       Date:  2016-03-21       Impact factor: 3.590

5.  Hsc70 rapidly engages tau after microtubule destabilization.

Authors:  Umesh K Jinwal; John C O'Leary; Sergiy I Borysov; Jeffrey R Jones; Qingyou Li; John Koren; Jose F Abisambra; Grant D Vestal; Lisa Y Lawson; Amelia G Johnson; Laura J Blair; Ying Jin; Yoshinari Miyata; Jason E Gestwicki; Chad A Dickey
Journal:  J Biol Chem       Date:  2010-03-22       Impact factor: 5.157

6.  Protective effects of a small molecule inhibitor ligand against hyperphosphorylated tau-induced mitochondrial and synaptic toxicities in Alzheimer disease.

Authors:  Jangampalli Adi Pradeepkiran; Manne Munikumar; Arubala P Reddy; P Hemachandra Reddy
Journal:  Hum Mol Genet       Date:  2021-12-27       Impact factor: 5.121

7.  Specific Peptide from the Novel W-Tau Isoform Inhibits Tau and Amyloid β Peptide Aggregation In Vitro.

Authors:  Raquel Cuadros; Mar Pérez; Daniel Ruiz-Gabarre; Félix Hernández; Vega García-Escudero; Jesús Avila
Journal:  ACS Chem Neurosci       Date:  2022-06-13       Impact factor: 5.780

8.  A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.

Authors:  Vega García-Escudero; Daniel Ruiz-Gabarre; Ricardo Gargini; Mar Pérez; Esther García; Raquel Cuadros; Ivó H Hernández; Jorge R Cabrera; Ramón García-Escudero; José J Lucas; Félix Hernández; Jesús Ávila
Journal:  Acta Neuropathol       Date:  2021-05-02       Impact factor: 15.887

9.  Blocking Effects of Human Tau on Squid Giant Synapse Transmission and Its Prevention by T-817 MA.

Authors:  Herman Moreno; Soonwook Choi; Eunah Yu; Janaina Brusco; Jesus Avila; Jorge E Moreira; Mutsuyuki Sugimori; Rodolfo R Llinás
Journal:  Front Synaptic Neurosci       Date:  2011-05-17

10.  Tau phosphorylation, aggregation, and cell toxicity.

Authors:  J Avila; I Santa-María; M Pérez; F Hernández; F Moreno
Journal:  J Biomed Biotechnol       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.